LEGN - Legend Biotech Corp

LEGN - Legend Biotech Corp

https://www.legendbiotech.com

Momentum: Bearish

Recent News

Powered by Alpha Vantage

Legend Biotech Appoints Carlos Santos as Chief Financial Officer

GlobeNewswire • 4 weeks ago • score: 0.14

SOMERSET, N.J., Aug. 18, 2025 ( GLOBE NEWSWIRE ) -- Legend Biotech Corporation ( NASDAQ: LEGN ) ( Legend Biotech ) , a global leader in cell therapy, today announced the appointment of Carlos Santos as the Company's Chief Financial Officer, effective immediately.

Company News for Aug 12, 2025

Zacks Commentary • 1 month ago • score: -0.08

Companies In The News Are: MU, AAON, LEGN, FNV.

Legend Biotech to Host Investor Conference Call on Second Quarter 2025 Results

GlobeNewswire • 1 month, 2 weeks ago • score: 0.11

SOMERSET, N.J., July 28, 2025 ( GLOBE NEWSWIRE ) -- Legend Biotech Corporation ( NASDAQ: LEGN ) ( Legend Biotech ) , a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Monday, August 11, 2025, to review second-quarter 2025 results.

Legend Biotech ( LEGN ) Surges 6.0%: Is This an Indication of Further Gains?

Zacks Commentary • 1 month, 4 weeks ago • score: 0.42

Legend Biotech (LEGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of new cell therapies for oncology and other indications in North America and internationally.

52W High

$52.31

52W Low

$27.34

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.28

Valuation

Fair

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

21.74

EV/EBITDA (<8 favorable)

-15.34

EV/Revenue (<3 favorable)

7.63

P/S (TTM) (<3 favorable)

8.36

P/B (<3 favorable)

6.43

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

1.30%

Institutions (25–75% balanced)

47.48%

Shares Outstanding

184,571,000

Float

162,766,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

796,838,000

Gross Profit (TTM)

97,932,000

EPS (TTM)

-1.78

Profit Margin (>10% good)

-0.41%

Operating Margin (TTM) (higher better)

-0.09%

ROE (TTM) (>15% strong)

-0.30%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

0.37

Momentum

Bearish momentum

Value

-1.1814

Previous

-1.1009

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025